31 Jan 2018 --- A recent review of S-Adenosyl-methionine (SAMe) has provided a broad perspective on the role, efficacy and safety of SAMe in the treatment of depression, neuropsychiatric disorders and co-morbid medical conditions. The authors conclude that SAMe supplementation holds promise for several neuropsychiatric conditions, which is significant because evidence supporting the safety and efficacy of SAMe in both psychiatric and medical illnesses could impact clinical decision making.
